Clinical Trial Update: Low-dose Interleukin-2 Treatment on Polymyalgia Rheumatica [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on low-dose interleukin-2 for polymyalgia rheumatica.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polymyalgia Rheumatica

Drugs mentioned

• Low-dose Interleukin-2 (interleukin-2)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Polymyalgia Rheumatica | Phase 2 | Status: UNKNOWN